TH31107B - Film-coated tablets for improved safety for the upper gastrointestinal tract. - Google Patents

Abstract

DC60 (06/07/54) A new oral dosage form to be delivered to the stomach containing Safe and effective doses of active ingredients are selected from a group that contains Emepronium bromide, doxycycline and tetracycline/antibiotic Other tetracycline/antibiotic preparations containing iron, quinidine, nonsteroidal anti-inflammatory drugs, alpernolol, ascorbic acid. ascorbic acid, captopril, theophylline, zidovoudine (AZT), bisphosphonates Anate (bisphosphonate) and its mixtures and pharmaceutically acceptable fillers, for which such oral dosage forms have Typically oval and is film-coated to enhance rapid esophageal transmission and avoid Irritation in the mouth, oral cavity, pharynx and esophagus A new oral dosage form to be delivered to the stomach contains Safe and effective dosage of active ingredients were selected from a group consisting of amepronium bromide, doxycycline, and tetracycline/antibiotic other tetracycline/antibiotic, iron-containing preparations Nonsteroidal anti-inflammatory drug quinidine, alpernolol, ascorbic acid, captol. Pril, (captopril), theophylline theophyline, zidovoudine (AZT), bisphosphonate and its mixtures and pharmaceutically acceptable fillers. The size of the oral dosage form is The picture is generally and is film-coated to enhance rapid esophageal transmission and avoid Irritation in the mouth, oral cavity, pharynx and esophagus. Patented drug.

Claims (9)

1. New oral dosage form that will be delivered to the stomach. The above dosage form includes: Safe and effective dosage of Selected active ingredients from the group containing tetracycline antibiotics, (tetracycline), preparations containing Iron, quinidine, (quinidine), non-steroidal anti-inflammatory drugs, alpernolol, ascorbic acid acid), captopril, theophylline, zidovoudine, bisphosphonate, or its mixtures. And the drug additive that Pharmacodynamically acceptable, such oral dosage form Has specific characteristics in that Typically oval and film coated. To promote fast esophageal transmission And avoid irritation in the mouth, mouth, throat, and esophagus, and includes dimensions from 0.58 to 2.16 cm, (0.23 to 0.85 in.), Length from 0.28 to 1.02 cm (0.11 to 0.4 in. ) And thickness from 0.19 to 0.76 cm (0.075 to 0.3 in.) 2. Dosage form according to claim 1, film-coated, soluble at pH from 1.2 to 5. 3. Dosage size according to claim 1 or 2, film-coated, was selected from a group containing hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxylic. Simethyl cellulose, methyl cellulose, ethyl cellulose, acrylic Resins, polyvinyl pyrolidone or gelatin or their mixtures 4. Dosage picture according to one of the above claims In which the dosage form is Modified wax figure Or a deceptive capsule (Figure 1-3) 5. Dosage picture according to one of the aforementioned claims Which active ingredients Was selected from a group containing emperonium bromide, doxycycline, iron-containing preparations, potassium chloride, quinidine, non-steroidal anti-inflammatory drugs. , L Prenolol, Ascorbic Acid, Captopril, Theophylline, Sidovudine, Rizedronate, Allen. Dronate or pamidronate or a mixture of it 6. Dosage size picture according to one of the aforementioned claims. The active ingredients were selected from a group containing civedronate, allendronate or pamidronate. 7. Dosage size picture according to one of the aforementioned claims. Which the size of the said drug Includes from 0.25% to 40% of the risedronate composition. 8. New oral dosage form based on one of the above claims. The dosage form of Dong is said to be a compressed tablet composed of particles of active ingredient and a pharmaceutical additive. 9. New oral dosage form based on one of the above claims in which the active ingredient particles Is film coated in itself